Beyond the Main Stage: A Showcase of the Next Wave of Korean Biotech Innovation at JPM Week 2026

As the global biomedical industry converges in San Francisco for the 44th Annual J.P. Morgan Healthcare Conference (JPM 2026), South Korea has firmly established itself as a dominant force in the Asia-Pacific biotech landscape. While industry giants like Samsung Biologics and Celltrion commanded attention on the Main Track at the Westin St. Francis, a dynamic wave of innovation was unfolding just blocks away.

On the evening of January 13, the KOTRA (Korea Trade-Investment Promotion Agency) Silicon Valley and Invest Korea (Korea’s national investment promotion agency) hosted the “2026 K-Bio Global Partnership” at The Marker San Francisco. This exclusive gathering served as a premier bridge between Korea’s burgeoning biotech start-up ecosystem and Silicon Valley’s top-tier investors. Moving beyond the established manufacturing prowess of Korea’s CDMO sector, the event highlighted a strategic shift toward high-value novel drug discovery, advanced delivery platforms, and AI-driven digital health solutions.

The event featured a dynamic Investor Relations (IR) Pitching Session involving 10 carefully selected start-ups in three thematic sections, followed by a Global Open Innovation Partnership reception. These innovators presented solutions ranging from non-opioid pain management and needle-free ocular treatments to AI-driven spatial biology and non-contact sleep diagnostics.

Therapeutic Pioneers Targeting Unmet Needs

The first pitching session focused on clinical-stage biopharma companies addressing critical unmet needs in pain management, oncology, and ophthalmology, showcasing assets with “first-in-class” potential. Leading the charge was iN Therapeutics, a spin-off from Daewoong Pharmaceutical, garnered significant interest with its non-opioid analgesic platform. Their lead asset, Aneratrigine (NaV1.7 Inhibitor), targets chronic pain without the dependency risks associated with opioids, a massive selling point in the current US healthcare climate. Having already secured EMA Phase 2 approval and executed a recent license-out deal with US-based Niroda Therapeutics exceeding $500 million, iN Therapeutics demonstrated the maturity of Korean drug discovery.

Another standout was NexThera, which aims to revolutionize ophthalmology. Currently, treatments for Macular Degeneration (AMD) often require invasive and uncomfortable intravitreal injections. NexThera presented NT-101, a first-in-class topical eye-drop therapy. By developing a proprietary formulation that allows drug delivery to the retina via drops, the company is addressing a massive patient burden. With U.S. Phase 1/2a trials ongoing, NexThera is striving to disrupt the multi-billion dollar anti-VEGF market with a patient-friendly alternative.

In the cardiovascular space, KarisBio presented its expertise in cell therapy. Under the leadership of stem cell expert Dr. Young-Sup Yoon, the company is accelerating U.S. clinical trials for Peripheral Artery Disease (PAD). Their proprietary non-virus-based technology differentiates iPSCs into high-purity endothelial cells, aiming to provide a functional vascular regeneration solution that overcomes the scalability challenges of traditional cell therapies.

VSPharmTech drew attention with its radiosensitizer, VS-101. As a disruptor in the oncology space, the company’s oral apoptosis enhancer is designed to boost the efficacy of radiotherapy in solid tumors. With Phase 2 trials ongoing in the U.S. for head and neck and breast cancers, and an FDA Orphan Drug Designation for glioblastoma secured in 2025, VSPharmTech is carving a niche in the radio-resistant tumor landscape.

Revolutionizing Drug Discovery and Delivery Platforms

The second session highlighted the “TechBio” convergence, featuring platform technologies that hold promise for revolutionizing how drugs are discovered and delivered. GenEdit, a company backed by Sequoia and Bow Capital, highlighted the critical importance of delivery in genetic medicine. CEO Kunwoo Lee presented the NanoGalaxy™ platform, a library of hydrophilic polymer nanoparticles capable of non-viral, tissue-specific delivery (targeting central nervous systems and muscle tissues) for genetic payloads such as mRNA and CRISPR. With strategic partnerships already in place with Genentech and Eli Lilly, GenEdit is tackling one of the biggest bottlenecks in gene therapy.

MEDIC Life Sciences introduced its MCAT™ platform, a functional genomics engine combining CRISPR with 3D human tumor organoids. By identifying “human-validated” targets that animal models often miss, MEDIC aims to significantly increase clinical success rates. The company, backed by LG and Hanmi Pharmaceutical, offers a solution to the high attrition rates in oncology drug development by utilizing high-fidelity functional data directly from patient tissue. They are also developing internal assets like a CDK7 inhibitor while scaling co-discovery partnerships.

Portrai showcased the power of spatial biology. Their AI-driven PortraiTARGET platform leverages spatial transcriptomics to discover and evaluate targets for Antibody-drug conjugates (ADCs) and radiopharmaceutical therapies (RPTs). By analyzing the tumor microenvironment in high resolution, Portrai offers precision stratification for patient selection, recently validating its approach through a joint R&D agreement with Celltrion.

AI and Digital Health Innovators that Redefine Patient Care

Reflecting Korea’s strong ICT infrastructure and the global trend toward digital transformation, the final session featured market-ready companies utilizing AI to streamline clinical workflows and patient care. Medipixel demonstrated its strength in cardiovascular diagnostics with Medipixel-XA. This AI-based software automates the analysis of coronary angiography, providing real-time, quantitative feedback to interventional cardiologists. With FDA 510(k) clearance already secured, Medipixel is scaling its global presence to reduce procedure times and improve diagnostic precision in cath labs.

Targeting the musculoskeletal rehabilitation market, EverEx presented its digital therapeutic (DTx) and remote therapeutic monitoring (RTM) solutions. Their platform, optimized for the U.S. reimbursement market, allows for AI-guided rehabilitation. Recognized as a Forbes Asia Top 100 startup, EverEx is aggressively expanding into U.S. orthopedic sectors, aligning with the shift toward value-based care.

Closing the presentations was Asleep, a sleep-tech company backed by Samsung Venture Investment. Their flagship solution, ApnoTrack, utilizes non-contact AI sound analysis to screen for sleep apnea via smartphone’s microphone with 94% accuracy. By eliminating the need for wearable devices, Asleep aims to establish a foundational API for sleep health within smart home ecosystems, already securing partnerships with major players like Samsung and L’Oréal.

Connecting the Dots in the Global Biotech Ecosystem

Beyond the pitches, the ‘Global Open Innovation Partnership Biz Meeting’ sparked intense networking for the 15 Korean biotech firms in attendance. Companies like SyntekaBio (AI drug discovery), EuBiologics (vaccine platforms), Oncocross (AI-driven drug repurposing), and VPIX Medical (handheld intraoperative imaging) actively pursued licensing and co-development deals with global stakeholders.

The “2026 K-Bio Global Partnership” highlighted that the Korean biotech industry has evolved beyond its reputation for manufacturing excellence. With a robust pipeline of novel therapeutics, cutting-edge drug delivery platforms, and practical AI applications, Korean innovators are increasingly well-positioned to become integral partners in the global biotech and healthcare ecosystem. As these emerging companies continue to secure FDA approvals and multinational partnerships, their presence in San Francisco this week signals a new era of “K-Bio” — one defined by agile, technology-driven companies ready to solve the world’s most critical medical challenges.

Author

Richard Chau